4 news items
Athira to Host Webinar Highlighting Potential for Fosgonimeton to Protect and Preserve Neuronal Health in Mild-to-Moderate Alzheimer's Disease Patients
ATHA
12 Jun 24
that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks
Athira Pharma Announces Proposed Settlement of Stockholder Derivative Action
ATHA
17 May 24
by the order, the following materials have been posted to the Investor Relations section of Athira's website
Athira Pharma Appoints Javier San Martin, M.D., as Chief Medical Officer
ATHA
15 Apr 24
of Directors approved the grant of the following equity award to Dr. San Martin as a material inducement to Dr. San Martin entering into employment
Athira Pharma Announces Publication of Preclinical Data Highlighting Fosgonimeton Treatment in Models of Alzheimer's Disease
ATHA
11 Apr 24
events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth
- Prev
- 1
- Next